Hermansky-Pudlak Syndrome: 11 Subtypes, Treatment Essentials
Rare genetic disorder causing albinism, bleeding issues, and potentially fatal lung fibrosis in affected subtypes.
Hermansky-Pudlak syndrome (HPS) is a rare autosomal recessive genetic disorder characterized by oculocutaneous albinism, bleeding diathesis due to platelet storage pool deficiency, and in some subtypes, progressive pulmonary fibrosis that can be fatal. It results from mutations in genes essential for the biogenesis of lysosome-related organelles (LROs), affecting pigmentation, hemostasis, and lung function.
What is Hermansky-Pudlak Syndrome?
HPS encompasses a group of at least 11 genetically distinct subtypes, each caused by biallelic mutations in specific genes involved in intracellular protein trafficking within LROs. These organelles are critical in melanocytes for melanin transport, platelets for dense granule formation, and type II pneumocytes in lungs for surfactant processing in affected subtypes. The syndrome was first described in 1959 by Czech physicians Farid Hermansky and Pavel Pudlak.
Prevalence is highest in Puerto Rico for HPS-1 (1:1,800), with global incidence estimated at 1:500,000–1,000,000. All subtypes share partial oculocutaneous albinism (OCA) and bleeding tendency, but pulmonary fibrosis (PF) penetrance varies: nearly 100% in HPS-1 by age 40–50, significant in HPS-2 and HPS-4, absent in others.
Who gets Hermansky-Pudlak Syndrome?
HPS affects all ethnic groups but shows founder effects in Puerto Rico (HPS-1, HPS-3), Turkey (HPS-5), and the Indian subcontinent (HPS-3). It presents from birth with hypopigmentation and manifests bleeding issues in infancy or early childhood. PF typically emerges in the third to fifth decade in susceptible types.
- High-risk populations: Puerto Rican descent for HPS-1 (most severe).
- Age of onset: Albinism at birth; bleeding by age 5–10; PF in 20s–50s for HPS-1/4.
Clinical Features
Skin Findings
Skin hypopigmentation varies from pale white to light brown, with increased freckling, solar damage, and skin cancer risk due to UV sensitivity. HPS-1 patients often exhibit severe hypopigmentation, while others have milder effects. Dermatologic changes include keratosis, skin thickening, dysplastic nevi, acanthosis nigricans-like lesions, and abnormally long eyelashes in some cases.
Hair Findings
Hair color ranges from white/silver to light brown, often with a silvery sheen in infancy darkening slightly with age. Hair is fragile, with increased breakage and sparse eyebrows/eyelashes.
Eye Features
Ocular manifestations include nystagmus (often horizontal from infancy), photophobia, reduced visual acuity (typically 20/100 to 20/400, legally blind), iris transillumination, foveal hypoplasia, and retinal hypopigmentation. Strabismus and high refractive errors are common. Vision stabilizes post-childhood but requires lifelong management.
Bleeding Tendencies
Platelet δ-storage pool deficiency impairs aggregation, causing mucocutaneous bleeding: epistaxis, gingival bleeding, easy bruising, menorrhagia, and postoperative hemorrhage. Aspirin/NSAIDs exacerbate risks; life-threatening bleeds occur with trauma/surgery.
Pulmonary Fibrosis
Highly penetrant in HPS-1 (80–100%), HPS-2, HPS-4; absent in others. Progressive interstitial lung disease starts with ground-glass opacities, progressing to fibrosis, honeycombing, and respiratory failure by age 40–50. Forced vital capacity (FVC) declines ~500 mL/year; median survival post-PF ~10 years.
Other Manifestations
- Colitis: Granulomatous colitis in ~15% (HPS-1 most), with bloody diarrhea, pain; resembles Crohn disease.
- Renal: Glomerular dysfunction in some.
- Immunologic: Neutropenia, infections in HPS-2.
- Ceroid lipofuscinosis: Tissue accumulation without neurodegeneration.
Types of Hermansky-Pudlak Syndrome
| Type | Gene | Key Features | PF Risk | Prevalence |
|---|---|---|---|---|
| HPS-1 | HPS1 | Severe OCA, bleeding, high PF risk, colitis | High | Common (Puerto Rico) |
| HPS-2 | AP3B1 | OCA, bleeding, neutropenia, PF | Moderate | Rare |
| HPS-3 | HPS3 | mild OCA, milder bleeding, no PF | None | Common (Puerto Rico) |
| HPS-4 | HPS4 | Severe like HPS-1, PF | High | Rare |
| HPS-5 | HPS5 | Mild OCA/bleeding, no PF | None | Turkey |
| HPS-6 | HPS6 | Mild, no PF | None | Rare |
| HPS-7 to 11 | Various (DTNBP1 etc.) | Limited data; variable mild features | Unknown/low | Very rare |
Cause / Pathogenesis
HPS arises from defects in biogenesis of lysosome-related organelles complex (BLOC-1,2,3), adaptor protein-3 (AP-3), and other complexes, disrupting cargo sorting in melanosomes, platelet dense granules, and lamellar bodies. This leads to hypopigmentation (impaired melanogenesis), bleeding (absent δ-granules), and PF (dysregulated surfactant/secretion in HPS-1/4).
Diagnosis
Diagnosis combines clinical triad (albinism + bleeding + family history), platelet electron microscopy (absent δ-granules), and genetic testing (NGS panels for 11 HPS genes). PF confirmed by PFTs, HRCT (ground-glass to fibrosis).
- Light microscopy: Giant granules in leukocytes (HPS-2,9).
- Genetic confirmation essential for subtype/prognosis.
Treatment / Management
Multidisciplinary: Hematology (desmopressin, antifibrinolytics, platelet transfusion for bleeds), Dermatology (sun protection, cancer screening), Ophthalmology (glasses, low-vision aids), Pulmonology (pirfenidone for PF, lung transplant).
- Bleeding: Avoid NSAIDs; DDAVP, tranexamic acid.
- PF: Pirfenidone slows decline; transplant curative but recurrence risk.
- Colitis: 5-ASA, steroids, infliximab.
- Supportive: UV protection, vision/hearing aids.
Prevention
Genetic counseling for carriers; prenatal testing. Sun avoidance, bleeding precautions.
Frequently Asked Questions
Is Hermansky-Pudlak syndrome curable?
No cure exists; management targets symptoms. Lung transplant for PF.
Does HPS always cause lung disease?
No, only subtypes 1,2,4; screen with annual PFTs/HRCT from age 10.
How is HPS inherited?
Autosomal recessive; 25% risk per pregnancy if both parents carriers.
Can people with HPS live normal lifespans?
Varies; non-PF types yes, HPS-1 median survival ~50 years with PF management.
What is the prognosis for HPS-1?
Guarded due to PF; early intervention improves outcomes.
References
- Hermansky-Pudlak Syndrome — Metabolic Support UK. 2023. https://metabolicsupportuk.org/condition/hermansky-pudlak-syndrome/
- Hermansky-Pudlak Syndrome – General Information — American Thoracic Society. 2020. https://www.thoracic.org/patients/lung-disease-week/2020/hermansky-pudlak-syndrome-week/general-info.php
- Hermansky Pudlak Syndrome — NORD (National Organization for Rare Disorders). 2024. https://rarediseases.org/rare-diseases/hermansky-pudlak-syndrome/
- Hermansky-Pudlak Syndrome — De Jesus et al., Pediatric Pulmonology. 2023. https://www.hpsnetwork.org/wp-content/uploads/HPS_Book-chapter-De-Jesus_Young.pdf
- Hermansky-Pudlak syndrome — MedlinePlus Genetics (NIH). 2024. https://medlineplus.gov/genetics/condition/hermansky-pudlak-syndrome/
Similar Articles
Read full bio of medha deb
